Differences in urinary prothrombin fragment 1 + 2 levels after total hip replacement in relation to venous thromboembolism and bleeding events

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 10, 2008, Pages 1671-1679

  Borris, Lars C ^a   Breindahl, M ^b   Lassen, M R ^c   Pap, A F ^d   Misselwitz, F ^d  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b R and D BESST TEST ApS   (Denmark)

^c HILLERØD HOSPITAL   (Denmark)

^d BAYER PHARMA AG   (Germany)

Author keywords

Bleeding event; Deep vein thrombosis; Prothrombin fragment 1 + 2; Pulmonary embolism; Total hip replacement; Urine

Indexed keywords

ENOXAPARIN; PROTHROMBIN; RIVAROXABAN; UNCLASSIFIED DRUG; XARELTO;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHLEBOGRAPHY; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; SYMPTOM; TOTAL HIP PROSTHESIS; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ARTHROPLASTY, REPLACEMENT, HIP; BIOLOGICAL MARKERS; BLOOD COAGULATION; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; PROTHROMBIN; VENOUS THROMBOEMBOLISM;

EID: 52449115143     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03120.x     Document Type: Article

References (10)

1. Agency for Healthcare Research and Quality. Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism. 2007; http://www.ahrq.gov/ downloads/pub/evidence/pdf/dvt/dvt.pdf, Accessed 17 August 2008.
2. NIH. Prevention of venous thrombosis and pulmonary embolism. NIH Consensus Development. JAMA 1986; 256: 744-9.
3. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S-400S.
4. Dahl OE, Aspelin T, Arnesen H, Seljeflot I, Kierulf P, Ruyter R, Lyberg T. Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Thromb Res 1995; 80: 299-306.
5. Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993; 91: 1877-83.
6. Herault JP, Bernat A, Pflieger AM, Lormeau JC, Herbert JM. Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase. J Pharmacol Exp Ther 1997; 283: 16-22.
7. Borris LC, Breindahl M, Ryge C, Sommer HM, Lassen MR. Prothrombin fragment 1 + 2 in urine as an indicator of sustained coagulation activation after total hip arthroplasty. Thromb Res 2007; 121: 369-76.
8. Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Kalebo P. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006; 4: 121-8.
9. Mueck W, Eriksson B, Borris L, Dahl O, Haas S, Huisman MV, Kakkar AK, Kalebo P, Muehlhofer E, Misselwitz F. Rivaroxaban for thromboprophylaxis in patients undergoing total hip replacement: Comparison of pharmacokinetics and pharmacodynamics with once- and twice-daily dosing. Blood 2006; 108: Abstract 903.
10. Brummel-Ziedins KE, Vossen CY, Butenas S, Mann KG, Rosendaal FR. Thrombin generation profiles in deep venous thrombosis. J Thromb Haemost 2005; 3: 2497-505.